Literature DB >> 21617889

Rosiglitazone improves spatial memory and decreases insoluble Aβ(1-42) in APP/PS1 mice.

Julie-Ann O'Reilly1, Marina Lynch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21617889     DOI： 10.1007/s11481-011-9282-7

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN： 1557-1890            Impact factor:   4.147


× No keyword cloud information.
  11 in total

1.  Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology.

Authors:  Luis Escribano; Ana-María Simón; Esther Gimeno; Mar Cuadrado-Tejedor; Rakel López de Maturana; Ana García-Osta; Ana Ricobaraza; Alberto Pérez-Mediavilla; Joaquín Del Río; Diana Frechilla
Journal:  Neuropsychopharmacology       Date:  2010-03-24       Impact factor: 7.853

2.  Subchronic memantine administration on spatial learning, exploratory activity, and nest-building in an APP/PS1 mouse model of Alzheimer's disease.

Authors:  Mohammed Filali; Robert Lalonde; Serge Rivest
Journal:  Neuropharmacology       Date:  2011-01-31       Impact factor: 5.250

3.  The effects of long-term treatment with metrifonate, a cholinesterase inhibitor, on cholinergic activity, amyloid pathology, and cognitive function in APP and PS1 doubly transgenic mice.

Authors:  L Liu; S Ikonen; T Heikkinen; T Tapiola; T van Groen; H Tanila
Journal:  Exp Neurol       Date:  2002-02       Impact factor: 5.330

4.  Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines.

Authors:  Jessica Koenigsknecht-Talboo; Gary E Landreth
Journal:  J Neurosci       Date:  2005-09-07       Impact factor: 6.167

5.  Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease.

Authors:  Monica Garcia-Alloza; Elissa M Robbins; Sandy X Zhang-Nunes; Susan M Purcell; Rebecca A Betensky; Susan Raju; Claudia Prada; Steven M Greenberg; Brian J Bacskai; Matthew P Frosch
Journal:  Neurobiol Dis       Date:  2006-10-05       Impact factor: 5.996

6.  Annexin A1: a central player in the anti-inflammatory and neuroprotective role of microglia.

Authors:  Simon McArthur; Enrico Cristante; Mario Paterno; Helen Christian; Federico Roncaroli; Glenda E Gillies; Egle Solito
Journal:  J Immunol       Date:  2010-10-20       Impact factor: 5.422

7.  Interleukin-4 mediates the neuroprotective effects of rosiglitazone in the aged brain.

Authors:  David J Loane; Brian F Deighan; Rachael M Clarke; Rebecca J Griffin; Aileen M Lynch; Marina A Lynch
Journal:  Neurobiol Aging       Date:  2007-10-22       Impact factor: 4.673

8.  Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer's disease.

Authors:  E M Toledo; N C Inestrosa
Journal:  Mol Psychiatry       Date:  2009-07-21       Impact factor: 15.992

9.  Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice.

Authors:  Ward A Pedersen; Pamela J McMillan; J Jacob Kulstad; James B Leverenz; Suzanne Craft; Gleb R Haynatzki
Journal:  Exp Neurol       Date:  2006-03-03       Impact factor: 5.330

10.  Hippocampal A beta 42 levels correlate with spatial memory deficit in APP and PS1 double transgenic mice.

Authors:  Jukka Puoliväli; Jun Wang; Taneli Heikkinen; Matti Heikkilä; Tero Tapiola; Thomas van Groen; Heikki Tanila
Journal:  Neurobiol Dis       Date:  2002-04       Impact factor: 5.996
View more
  19 in total

1.  Neuroinflammation and cognitive dysfunction in chronic disease and aging.

Authors:  Amy M Hein; M Kerry O'Banion
Journal:  J Neuroimmune Pharmacol       Date:  2012-01-18       Impact factor: 4.147

Review 2.  Therapeutic potential of nuclear receptor agonists in Alzheimer's disease.

Authors:  Miguel Moutinho; Gary E Landreth
Journal:  J Lipid Res       Date:  2017-03-06       Impact factor: 5.922

Review 3.  Type 2 diabetes and cognitive compromise: potential roles of diabetes-related therapies.

Authors:  Efrat Kravitz; James Schmeidler; Michal Schnaider Beeri
Journal:  Endocrinol Metab Clin North Am       Date:  2013-09       Impact factor: 4.741

Review 4.  Mitochondrial dysfunction in Alzheimer's disease: Role in pathogenesis and novel therapeutic opportunities.

Authors:  Judit M Perez Ortiz; Russell H Swerdlow
Journal:  Br J Pharmacol       Date:  2019-03-06       Impact factor: 8.739

Review 5.  Insulin resistance in Alzheimer's disease.

Authors:  Kelly T Dineley; Jordan B Jahrling; Larry Denner
Journal:  Neurobiol Dis       Date:  2014-09-16       Impact factor: 5.996

6.  Combined Liver X Receptor/Peroxisome Proliferator-activated Receptor γ Agonist Treatment Reduces Amyloid β Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 Mice.

Authors:  Rebecca Skerrett; Mateus P Pellegrino; Brad T Casali; Laura Taraboanta; Gary E Landreth
Journal:  J Biol Chem       Date:  2015-07-10       Impact factor: 5.157

7.  Effects of curcumin on synapses in APPswe/PS1dE9 mice.

Authors:  Yingkun He; Pengwen Wang; Peng Wei; Huili Feng; Ying Ren; Jinduo Yang; Yingxue Rao; Jing Shi; Jinzhou Tian
Journal:  Int J Immunopathol Pharmacol       Date:  2016-03-08       Impact factor: 3.219

Review 8.  Reassessment of Pioglitazone for Alzheimer's Disease.

Authors:  Ann M Saunders; Daniel K Burns; William Kirby Gottschalk
Journal:  Front Neurosci       Date:  2021-06-16       Impact factor: 4.677

Review 9.  Nuclear receptors in neurodegenerative diseases.

Authors:  Rebecca Skerrett; Tarja Malm; Gary Landreth
Journal:  Neurobiol Dis       Date:  2014-05-27       Impact factor: 5.996

Review 10.  Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain.

Authors:  D Allan Butterfield; Fabio Di Domenico; Eugenio Barone
Journal:  Biochim Biophys Acta       Date:  2014-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.